Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 146,394 shares at $16.25 ($2.4M) on 2025-10-13, disclosed to the SEC on 2025-10-14.
Scheduled sale ($2.4M) by President & Immunovant CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.30 | 104,940 | $1.7M | 71.7% |
| 2 | $16.25 | 20,727 | $337K | 14.1% |
| 3 | $16.25 | 20,727 | $337K | 14.1% |
| Total | $16.29 avg | 146,394 | $2.4M | 100% |
| Filing → |
| ROIV | SELL | 2026-09-01 | $7.2M | — | Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |